Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Genetics and Molecular Research : GMR
|
September 9, 2015
Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes
Y Han, Q Li, B H Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 11, 2012
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer
Y Fan, B H Xu, P Yuan, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
June 19, 2025
[Comparison of the efficacy, safety, and cost-effectiveness of trastuzumab biosimilar HLX02 and the originator combined with pertuzumab and chemotherapy in the neoadjuvant treatment of patients with HER-2-positive breast cancer]
Z X Lei, D Sang, B Lan, et al.
ESMO Open
|
September 6, 2024
QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Q-Y Zhang, R-G Cai, G-H Song, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
October 25, 2021
[Analysis of the effect of ipsilateral supraclavicular lymph node metastasis on the prognosis of N3 breast cancer]
Abudureheiyimu Nilupai, J Y Wang, Q Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
August 14, 2023
[Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study]
M Xiu, Y Lu, X Wang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
May 29, 2019
[Feasibility and toxicity of EC-T dose-dense adjuvant chemotherapy: A real world study in Chinese early-stage breast cancer patients with high recurrence risk]
J N Wang, Y X Mu, Q Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
February 20, 2022
[Efficacy and survival outcomes of dose-dense carboplatin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer]
Y Liu, M Xiu, X Wang, et al.
Scientific Reports
|
September 22, 2016
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
F Du, P Yuan, Z T Zhao, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Genetics and Molecular Research : GMR
|
September 9, 2015
Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes
Y Han, Q Li, B H Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 11, 2012
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer
Y Fan, B H Xu, P Yuan, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
June 19, 2025
[Comparison of the efficacy, safety, and cost-effectiveness of trastuzumab biosimilar HLX02 and the originator combined with pertuzumab and chemotherapy in the neoadjuvant treatment of patients with HER-2-positive breast cancer]
Z X Lei, D Sang, B Lan, et al.
ESMO Open
|
September 6, 2024
QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Q-Y Zhang, R-G Cai, G-H Song, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
October 25, 2021
[Analysis of the effect of ipsilateral supraclavicular lymph node metastasis on the prognosis of N3 breast cancer]
Abudureheiyimu Nilupai, J Y Wang, Q Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
August 14, 2023
[Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study]
M Xiu, Y Lu, X Wang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
May 29, 2019
[Feasibility and toxicity of EC-T dose-dense adjuvant chemotherapy: A real world study in Chinese early-stage breast cancer patients with high recurrence risk]
J N Wang, Y X Mu, Q Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
February 20, 2022
[Efficacy and survival outcomes of dose-dense carboplatin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer]
Y Liu, M Xiu, X Wang, et al.
Scientific Reports
|
September 22, 2016
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
F Du, P Yuan, Z T Zhao, et al.
Page
of 1